Specify a stock or a cryptocurrency in the search bar to get a summary
StemRIM
4599StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. The company develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy. Its pre-clinical stage products include PJ2 and PJ3 to treat multiple tissue damage disease; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy. StemRIM was incorporated in 2006 and is based in Ibaraki, Japan. Address: Saito Bio-Incubator, Ibaraki, Japan, 567-0085
Analytics
WallStreet Target Price
107 117.5 JPYP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 4599
Dividend Analytics 4599
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 4599
Stock Valuation 4599
Financials 4599
Results | 2019 | Dynamics |